Search tips
Search criteria 


Logo of molmedLink to Publisher's site
Mol Med. 1997 April; 3(4): 273–283.
PMCID: PMC2230072

Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.


BACKGROUND: The overexpression or amplification of tumor suppressor and proto-oncogenes are important factors in the progression of breast cancer. Recent attention has focused on the cyclin genes, whose involvement in signal transduction pathways regulate cell cycle progression. The amplification of the cyclins D1 and D3 genes usually leads to loss of normal growth control and is thought to play an important growth regulatory role in tumor development and progression. In this report, we investigate the association of altered cyclin expression with other prognostic indicators (histological grade, lymph node status, estrogen receptor, p53, and c-erbB-2) in the progression of human breast cancer. MATERIALS AND METHODS: Surgical tumor specimens were obtained from 16 breast tubular ductal, and invasive ductal carcinomas and grafted onto gnotobiotic nude (nu/nu) mice. The expression diversity and distribution of the localization of the protein products of the c-erbB-2, cyclins D1 and D3, p53, and estrogen receptor were characterized immunohistochemically and the results in the original tumor (T0) were compared with those in the tumors that developed in nude mice (T1) xenografts. RESULTS: The T0 tumors exhibited a diversity of cellular morphology in the tumor matrix and diversity in expression of these proteins. These specific changes were also preserved in the T1 tumors. Whereas 67% of the T1 tumors exhibited high numbers of estrogen receptorpositive nuclei, only 50% of these tumors grew when grafted onto nude mice. The histological grade (14/15 were G2 to G3) and metastatic malignancy in the lymph nodes (10/15) did not appear to be related to tumor growth in the nude mouse. There was no relationship between those tumors which exhibited high percentages of c-erbB-2- and p53-positive cells and growth in nude mice. A strong association (p < 0.001) was observed between the overexpression of cyclin D1 transcripts in the T0 tumors and the continued growth of the T1 tumors in nude mice. In the T1 tumors, both cyclins D1 and D3, estrogen receptor, and p53 were observed in 49% to 86% of the cells of the T1 tumors examined; the number of cells expressing c-erbB-2 protein varied widely in these tumors. CONCLUSIONS: The results indicate that the tumor matrix exhibits a diversity in the level of phenotypic expression of genes involved in cellular growth of breast tumors in both the T0 or T1 host environment. Changes in cyclin activity appear to correlate with the vigorous level of breast tumor growth and progression.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat. 1996;39(1):69–86. [PubMed]
  • Brünner N, Boysen B, Rømer J, Spang-Thomsen M. The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat. 1993;24(3):257–264. [PubMed]
  • Chen JC, Shuler CF, Zhang CX, Schuller DE, Milo GE. Histopathologic comparison between human oral squamous cell carcinomas and their xenografts in nude mice. Oral Surg Oral Med Oral Pathol. 1991 Apr;71(4):457–463. [PubMed]
  • Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990 Feb 1;50(3):717–721. [PubMed]
  • Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev. 1990 Feb;8(4):285–297. [PubMed]
  • Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, et al. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer. 1991 Jan 2;47(1):66–71. [PubMed]
  • Mehta RR, Graves JM, Warso MA, Das Gupta TK. Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice. Br J Cancer. 1995 Nov;72(5):1160–1164. [PMC free article] [PubMed]
  • Lewko WM, Vaghmar R, Hubbard D, Moore M, He YJ, Chang L, Husseini S, Wallwork K, Thurman GB, Oldham RK. Cultured cell lines from human breast cancer biopsies and xenografts. Breast Cancer Res Treat. 1990 Dec;17(2):121–129. [PubMed]
  • Quénel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995 Sep;35(3):283–291. [PubMed]
  • Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, Farrus B, Latre ML, Gimenez N, Hage M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996 Jul-Aug;16(4B):2295–2300. [PubMed]
  • Becker K, Dosch J, Gregel CM, Martin BA, Kaina B. Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 1996 Jul 15;56(14):3244–3249. [PubMed]
  • Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer. 1996 Jan;73(1):29–35. [PMC free article] [PubMed]
  • Cox LA, Chen G, Lee EY. Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res Treat. 1994;32(1):19–38. [PubMed]
  • Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. 1995;427(3):229–241. [PubMed]
  • Allred DC, Elledge R, Clark GM, Fuqua SA. The p53 tumor-suppressor gene in human breast cancer. Cancer Treat Res. 1994;71:63–77. [PubMed]
  • Andrews BJ, Mason SW. Gene expression and the cell cycle: a family affair. Science. 1993 Sep 17;261(5128):1543–1544. [PubMed]
  • Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res. 1994 Nov-Dec;14(6B):2465–2472. [PubMed]
  • Strobl JS, Wonderlin WF, Flynn DC. Mitogenic signal transduction in human breast cancer cells. Gen Pharmacol. 1995 Dec;26(8):1643–1649. [PubMed]
  • Wuarin J, Nurse P. Regulating S phase: CDKs, licensing and proteolysis. Cell. 1996 Jun 14;85(6):785–787. [PubMed]
  • Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994 Nov;102(5):695–698. [PubMed]
  • Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996 Apr 22;69(2):92–99. [PubMed]
  • Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. Gene. 1995 Jun 14;159(1):83–96. [PubMed]
  • Bartkova J, Zemanova M, Bartek J. Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer. 1996 Jan 26;65(3):323–327. [PubMed]
  • Chen J, Milo GE, Shuler CF, Schuller DE. Xenograft growth and histodifferentiation of squamous cell carcinomas of the pharynx and larynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Feb;81(2):197–202. [PubMed]
  • Yohn J, Lehman TA, Kurian P, Ribovich M, Milo GE. Benzo[a]pyrene diol epoxide I modification of DNA in human skin xenografts. J Invest Dermatol. 1988 Oct;91(4):363–368. [PubMed]
  • Wani G, D'Ambrosio SM. Differential expression of the O6-alkylguanine-DNA alkyltransferase gene in normal human breast and skin tissue: in situ mapping of cell type-specific expression. Mol Carcinog. 1995 Mar;12(3):177–184. [PubMed]
  • Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. [PubMed]
  • Allred DC, O'Connell P, Fuqua SA, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994;32(1):13–18. [PubMed]
  • Ozzello L, de Rosa CM, Cantell K, Kauppinen HL, Habif DV., Sr Regression of human breast cancer xenografts in response to intralesional treatment with interferons alpha and gamma potentiated by tumor necrosis factor. J Interferon Cytokine Res. 1995 Oct;15(10):839–848. [PubMed]
  • Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1996 Jun 7;1287(2-3):77–102. [PubMed]
  • Carson DA, Lois A. Cancer progression and p53. Lancet. 1995 Oct 14;346(8981):1009–1011. [PubMed]
  • Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 1;74(5):1601–1606. [PubMed]
  • Clarke R, Skaar T, Baumann K, Leonessa F, James M, Lippman J, Thompson EW, Freter C, Brunner N. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat. 1994;31(2-3):237–248. [PubMed]
  • Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM. Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features. Int J Cancer. 1994 Nov 1;59(3):351–356. [PubMed]
  • Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 1995 May 6;345(8958):1181–1182. [PubMed]
  • Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer. 1993 Aug 19;55(1):51–56. [PubMed]
  • Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993 Dec 15;72(12):3641–3647. [PubMed]
  • Martinazzi M. Expression of p53 oncoprotein in different histological types of breast carcinoma. Am J Pathol. 1994 Jan;144(1):205–205. [PubMed]
  • Merlo GR, Venesio T, Taverna D, Marte BM, Callahan R, Hynes NE. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene. 1994 Feb;9(2):443–453. [PubMed]
  • Smith HS, Lu Y, Deng G, Martinez O, Krams S, Ljung BM, Thor A, Lagios M. Molecular aspects of early stages of breast cancer progression. J Cell Biochem Suppl. 1993;17G:144–152. [PubMed]
  • Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat. 1994;32(1):39–47. [PubMed]
  • Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res. 1996 May-Jun;16(3A):1301–1304. [PubMed]
  • Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996 Jul;74(2):208–215. [PMC free article] [PubMed]
  • Singleton TP, Strickler JG. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu. 1992;27(Pt 1):165–190. [PubMed]
  • Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, Steplewski Z, James W, Perras J. A novel model of a metastatic human breast tumour xenograft line. Br J Cancer. 1993 Aug;68(2):274–276. [PMC free article] [PubMed]
  • Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol. 1995 Feb;26(2):210–216. [PubMed]
  • Allred DC, O'Connell P, Fuqua SA. Biomarkers in early breast neoplasia. J Cell Biochem Suppl. 1993;17G:125–131. [PubMed]
  • Szöllösi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 1995 Nov 15;55(22):5400–5407. [PubMed]
  • Stanton PD, Cooke TG, Forster G, Smith D, Going JJ. Cell kinetics in vivo of human breast cancer. Br J Surg. 1996 Jan;83(1):98–102. [PubMed]
  • Han EK, Sgambato A, Jiang W, Zhang YJ, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein IB. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene. 1995 Mar 2;10(5):953–961. [PubMed]
  • Sgambato A, Han EK, Zhang YJ, Moon RC, Santella RM, Weinstein IB. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced rat mammary tumors. Carcinogenesis. 1995 Sep;16(9):2193–2198. [PubMed]
  • McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, Horne CH. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ